Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : IGT Pharma (V.IGT) Anti-Cancer Blockbuster!! -- Ignore unavailable to you. Want to Upgrade?

To: Stephen O who wrote (55)	2/4/1999 1:04:00 AM
From: Pawl	Read Replies (1) \| Respond to of 86

News ---------------------------------------------------------------------- IGT Pharma neurological drug development progressing IGT Pharma Inc IGT Shares issued 8,819,820 Feb 2 close $0.82 Wed 3 Feb 99 News Release Mr. Bruce Schmidt reports The company has received positive preliminary results from testing performed at the Royal Danish School of Pharmacy, Copenhagen. The objective of the testing was to provide data relating to the performance of IGT's new series of specialized amino acid type compounds on certain brain receptors. Specifically, drugs which interact with a new class of receptor called the metabotropic glutamate receptors (mGluRs) now represent the leading edge of neurological drug development. The mGluRs may provide medical science with a better way of treating a range of neurological conditions including stroke, epilepsy, anxiety, movement control and drug dependence. The advantage of mGluRs is that certain receptor types tend to be associated with certain disorders thus allowing for highly targeted treatments with only limited side effects. Preliminary data resulting from the study show that IGT's first series of compounds referenced as IGT440101 are specifically active as blockers of the mGluR 1 receptor. This receptor has been identified as controlling the levels of excitability of brain cells (neurons) which is implicated in conditions such as stroke and epilepsy. With these findings, IGT is now proceeding to expand its testing into animal models in preparation for a decision to enter human clinical trials. IGT's strategy will be to develop these, as well as other neurological drugs, with pharmaceutical partners with existing marketing channels. To that end, discussions are under way which may lead to meaningful longer term relationships with multinational pharmaceutical organizations engaged in the neurological treatment markets. ----------------------------------------------------------------------